Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations

Abstract

Background:

Brain atrophy in multiple sclerosis (MS) patients is present since the very early stages of the disease and it has been related to long-term disability.

Objective:

To estimate brain volume (BV) at 15 years after a clinically isolated syndrome (CIS) and to evaluate its relationship with disease outcomes.

Methods:

From a prospective cohort including patients presenting with a CIS, 54 patients with a brain magnetic resonance imaging (MRI) performed 15 years after CIS were included. Brain parenchymal fraction (BPF), grey matter fraction (GMF) and white matter fraction (WMF) at 15-year follow-up were obtained. Regression analyses were conducted to predict BV loss and reaching an Expanded Disability Status Scale (EDSS) of 3.0 in that 15-year period.

Results:

In multivariable analyses, lower values of BPF and WMF were significantly associated with being male, presenting 3–4 Barkhof criteria at baseline, presenting a second relapse, and with a decision to start treatment. In the multivariable logistic regression analysis, only lower GMF was associated with a greater risk of reaching EDSS 3.0 (odds ratio (OR) = 0.24, p = 0.028).

Conclusion:

Lower BPF and WMF 15 years after CIS are associated with previous markers of inflammatory disease. Lower GMF 15 years after a CIS is associated with an increased risk of reaching an EDSS of 3.0.

Keywords

Multiple sclerosis atrophy grey matter clinically isolated syndrome

Get full access to this article

View all access options for this article.

References

Frohman

Racke

Raine

. Multiple sclerosis – The plaque and its pathogenesis. N Engl J Med 2006; 354(9): 942–955.

Zivadinov

. Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.J Neuroimaging 2005; 15(1): 27–36.

Filippi

. MRI measures of neurodegeneration in multiple sclerosis: Implications for disability, disease monitoring, and treatment. J Neurol 2015; 262(1): 1–6.

De Stefano

Giorgio

Battaglini

et al . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74(23): 1868–1876.

De Stefano

Stromillo

Giorgio

et al . Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 93–99.

Dalton

Chard

Davies

et al . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127(5): 1101–1107.

Calabrese

Rinaldi

Mattisi

et al . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77(3): 257–263.

Perez-Miralles

Sastre-Garriga

Tintore

et al . Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013; 19(14): 1878–1886.

Zivadinov

Havrdová

Bergsland

et al . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013; 268(3): 831–841.

10.

Jacobsen

Hagemeier

Myhr

K-M

et al . Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014; 85(10): 1109–1115.

11.

Zivadinov

Bergsland

Dolezal

et al . Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 2013; 34(10): 1931–1939.

12.

Fisniku

Chard

Jackson

et al . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64(3): 247–254.

13.

Tintore

Rovira

Río

et al . Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(7): 1863–1874.

14.

Barkhof

Filippi

Miller

et al . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120(Pt. 11): 2059–2069.

15.

Tintoré

Rovira

Martínez

et al . Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 702–706.

16.

Smith

. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17(3): 143–155.

17.

Fisher

Lee

J-C

Nakamura

et al . Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008; 64(3): 255–265.

18.

Steenwijk

Daams

Pouwels

PJW

et al . What explains gray matter atrophy in long-standing multiple sclerosis? Radiology 2014; 272(3): 832–842.

19.

Antulov

Carone

Bruce

et al . Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. J Neuroimaging 2011; 21(3): 210–218.

20.

Tiberio

Chard

Altmann

et al . Gray and white matter volume changes in early RRMS: A 2-year longitudinal study. Neurology 2005; 64(6): 1001–1007.

21.

Sastre-Garriga

Ingle

Chard

et al . Grey and white matter volume changes in early primary progressive multiple sclerosis: A longitudinal study. Brain 2005; 128(Pt. 6): 1454–1460.

22.

Vidal-Jordana

Sastre-Garriga

Pérez-Miralles

et al . Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19(9): 1175–1181.

23.

Vidal-Jordana

Sastre-Garriga

Pérez-Miralles

et al . Brain volume loss during the first year of interferon-beta treatment in multiple sclerosis: Baseline inflammation and regional brain volume dynamics. J Neuroimaging 2016; 26(5): 532–538.

24.

Coffey

Lucke

Saxton

et al . Sex differences in brain aging: A quantitative magnetic resonance imaging study. Arch Neurol 1998; 55(2): 169–179.

25.

Rojas

Sánchez

Patrucco

et al . Structural sex differences at disease onset in multiple sclerosis patients. Neuroradiol J 2016; 29(5): 368–371.

26.

Vidal-Jordana

Sastre-Garriga

Rovira

et al . Treating relapsing-remitting multiple sclerosis: Therapy effects on brain atrophy. J Neurol 2015; 262(12): 2617–2626.

27.

Ciampi

Pareto

Sastre-Garriga

et al . Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler 2017; 23: 556–566.

28.

Confavreux

Vukusic

Adeleine

. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126(Pt. 4): 770–782.

29.

Koch

Kingwell

Rieckmann

et al . The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81(9): 1039–1043.

30.

Vrenken

Jenkinson

Horsfield

et al . Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013; 260(10): 2458–2471.